Promising nanotherapy in treating leishmaniasis

Promising nanotherapy in treating leishmaniasis

[Display omitted] •An overview of the importance of nanotechnology to treatment of leishmaniasis.•Will be presented some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis.•The role of nanocarriers in pharmaceutical research have provided great promise...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics Vol. 547; no. 1-2; pp. 421 - 431
Main Authors: de Souza, Aline, Marins, Débora Soares Souza, Mathias, Samir Leite, Monteiro, Lis Marie, Yukuyama, Megumi Nishitani, Scarim, Cauê Benito, Löbenberg, Raimar, Bou-Chacra, Nádia Araci
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 25-08-2018
Subjects:
Drug delivery systems
Drug targeting
Human leishmaniasis
Nanotechnology
Nanotherapeutics
Treatment
MILT
SESE
PRM
NanoDDS
SLN
AMB
TFL-L
DMPC
HSH
PAHO
CHOL
DOPC
EE
Nanotherapeutics
DPPG
AgNPs
PACA
TiAgNps
MONPCG
PGA
NFOH
VL
DMSA
NE
PCL
Drug delivery systems
NLC
PLA
MgONPs
LPS
Human leishmaniasis
L-AMB
NTDs
PDI
Nano-D-AMB
Drug targeting
Nano-D-AMB-MG
DPPA
DPPC
DMPG
DOPG
DSPE
QauNP
CL
DOPS
RIF
PLGA
Treatment
HIV
PBCA
MCL
Nanotechnology
SeNPs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •An overview of the importance of nanotechnology to treatment of leishmaniasis.•Will be presented some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis.•The role of nanocarriers in pharmaceutical research have provided great promise for more efficient and safe drug therapy.•A considerable number of studies reported in the literature that demonstrate the in vivo efficacy of these therapies.•Careful analysis is needed to deal with the problem of why these new therapies are not available in the market. Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with this infection. Nevertheless, only a few effective drugs are available, and each has a particular disadvantage; toxicity and long-term regimens compromise most chemotherapeutic options, which decreases patient compliance and adherence to the treatment and consequently the emergence of drug-resistant strains. Nano drug delivery systems (NanoDDS) can direct antileishmanial drug substances for intracellular localization in macrophage-rich organs such as bone marrow, liver, and spleen. This strategy can improve the therapeutic efficacy and reduce the toxic effects of several antileishmanial drug substances. This review is an effort to comprehensively compile recent findings, with the aim of advancing understanding of the importance of nanotechnology for treating leishmaniases.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2018.06.018